Emerging Stocks Down Under 29 September 2020: Recce Pharmaceuticals, Energy One, 9Spokes

Emerging Stocks Down Under Edition #2

Recce Pharmaceuticals: Antibiotic resistance may have met its match

Today in Emerging Stocks Down Under it’s been a spectacular re-rating. The drug developer Recce Pharmaceuticals could be had for just 23 cents a share back on 24 March 2020.  It’s since gone up about sevenfold, thanks to a succession of favourable announcements related to Recce’s lead compound, a fast acting, broad-spectrum antibiotic called Recce 327.

Also in today's edition, a look at energy trading and logistics software developer Energy One and application marketplace 9Spokes.

Get access to all editions through a 2-week FREE TRIAL. No charge on sign up.

Click here to read the previous edition of Emerging Stocks Down Under published 22 September 2020

For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter

Please register or upgrade your plan to access this content.

Save $$$
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$69
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$59
BILLED ANNUALLY
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks